This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Trevi Therapeutics, Inc.
Drug Names(s): PW4142, T111
Description: Nalbuphine ER is an extended release formulation of nalbuphine (Nubain, an intravenous medication), a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. It binds to mu, kappa, and delta opioid receptors, but not to sigma receptors. It is primarily a kappa agonist/partial mu antagonist analgesic.
Nalbuphine ER was originally developed by Penwest Pharmaceuticals.
Endo and Penwest
In August 2010, Penwest Pharmaceuticals announced that it has entered into a merger agreement under which Endo Pharmaceuticals has agreed to acquire all of the common stock of Penwest for $5.00 per share in cash. The acquisition was completed in November 2010.
Endo and Trevi
In 2011, Trevi acquired the worldwide license from Endo for Nalbuphine ER.
Partners: Endo International plc
Nalbuphine ER News
Additional information available to subscribers only: